Solifenacin succinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for solifenacin succinate and what is the scope of freedom to operate?
Solifenacin succinate
is the generic ingredient in three branded drugs marketed by Astellas, Accord Hlthcare, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal Pharms Co, Annora Pharma, Aurobindo Pharma, Austarpharma, Breckenridge, Chartwell Rx, Cipla, Glenmark Speclt, Jubilant Generics, Lannett Co Inc, Macleods Pharms Ltd, MSN, Qilu, Rising, Sciegen Pharms Inc, Strides Pharma, Sunshine, Teva Pharms Usa, Unichem, Watson Labs Inc, and Zydus Pharms, and is included in twenty-seven NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Solifenacin succinate has twenty-three patent family members in twenty-one countries.
There are twenty-nine drug master file entries for solifenacin succinate. Twenty-seven suppliers are listed for this compound.
Summary for solifenacin succinate
International Patents: | 23 |
US Patents: | 1 |
Tradenames: | 3 |
Applicants: | 26 |
NDAs: | 27 |
Drug Master File Entries: | 29 |
Finished Product Suppliers / Packagers: | 27 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Clinical Trials: | 58 |
Patent Applications: | 3,068 |
Drug Prices: | Drug price trends for solifenacin succinate |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for solifenacin succinate |
What excipients (inactive ingredients) are in solifenacin succinate? | solifenacin succinate excipients list |
DailyMed Link: | solifenacin succinate at DailyMed |
Recent Clinical Trials for solifenacin succinate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai University of Traditional Chinese Medicine | N/A |
Longhua Hospital | N/A |
Hikma Pharma | Phase 1 |
Pharmacology for solifenacin succinate
Drug Class | Cholinergic Muscarinic Antagonist |
Mechanism of Action | Cholinergic Muscarinic Antagonists |
Medical Subject Heading (MeSH) Categories for solifenacin succinate
Anatomical Therapeutic Chemical (ATC) Classes for solifenacin succinate
Paragraph IV (Patent) Challenges for SOLIFENACIN SUCCINATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VESICARE LS | Oral Suspension | solifenacin succinate | 1 mg/mL | 209529 | 1 | 2021-05-27 |
VESICARE | Tablets | solifenacin succinate | 5 mg and 10 mg | 021518 | 1 | 2009-04-08 |
US Patents and Regulatory Information for solifenacin succinate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal Pharms Co | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 209719-001 | May 20, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sunshine | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 213346-002 | Apr 13, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sunshine | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 213346-001 | Apr 13, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alkem Labs Ltd | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 210224-002 | May 20, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for solifenacin succinate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astellas | VESICARE | solifenacin succinate | TABLET;ORAL | 021518-001 | Nov 19, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Astellas | VESICARE | solifenacin succinate | TABLET;ORAL | 021518-002 | Nov 19, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for solifenacin succinate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Eurasian Patent Organization | 201291276 | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ СОЛИФЕНАЦИН | ⤷ Sign Up |
Eurasian Patent Organization | 023294 | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СОЛИФЕНАЦИН (PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN) | ⤷ Sign Up |
Cyprus | 1117816 | ⤷ Sign Up | |
South Korea | 20130093010 | PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for solifenacin succinate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0801067 | SPC/GB04/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816 |
0801067 | C00801067/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006 |
0801067 | 04C0032 | France | ⤷ Sign Up | PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.